CO5450246A1 - VACCINE - Google Patents

VACCINE

Info

Publication number
CO5450246A1
CO5450246A1 CO00052321A CO00052321A CO5450246A1 CO 5450246 A1 CO5450246 A1 CO 5450246A1 CO 00052321 A CO00052321 A CO 00052321A CO 00052321 A CO00052321 A CO 00052321A CO 5450246 A1 CO5450246 A1 CO 5450246A1
Authority
CO
Colombia
Prior art keywords
protein
seq
prostase
vaccine
fusion
Prior art date
Application number
CO00052321A
Other languages
Spanish (es)
Inventor
Silva Teresa Cabezon
Dillon Davin Clifford
Original Assignee
Smithkline Beecham Corp
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/352,616 external-priority patent/US6395278B1/en
Priority claimed from US09/439,313 external-priority patent/US6329505B1/en
Application filed by Smithkline Beecham Corp, Corixa Corp filed Critical Smithkline Beecham Corp
Publication of CO5450246A1 publication Critical patent/CO5450246A1/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una proteína de fusión que incluye una proteína prostasa, fragmento u homologos de la misma, unida a un acompañante heterológo de fusión. Una proteína de acuerdo con la reivindicación 1, en la que el antígeno prostasa se selecciona del grupo formado por la SEQ ID N° 5, SEO ID N° 6, SEQ ID N° 7 y SEQ ID N° 8.1 Una vacuna de acuerdo con la reivindicación 10 u 11, en la que el adyuvante comprende 3D-MPL, QS21, un oligonucleótido CpG o un éter o éster de polietileno.1 Uso de una proteína o de un ácido nucleico de acuerdo con las presentes reivindicaciones, para la fabricación de una vacuna para tratar inmunoterapéuticamente un paciente que padece cáncer u otros tumores asociados con una prostasa.A fusion protein that includes a prostase protein, fragment or homologs thereof, attached to a fusion heterolologous companion. A protein according to claim 1, wherein the prostase antigen is selected from the group consisting of SEQ ID No. 5, SEO ID No. 6, SEQ ID No. 7 and SEQ ID No. 8.1 A vaccine according to claim 10 or 11, wherein the adjuvant comprises 3D-MPL, QS21, a CpG oligonucleotide or a polyethylene ether or ester. 1 Use of a protein or a nucleic acid according to the present claims, for the manufacture of a vaccine to immunotherapeutically treat a patient suffering from cancer or other tumors associated with a prostase.

CO00052321A 1999-07-13 2000-07-12 VACCINE CO5450246A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/352,616 US6395278B1 (en) 1997-02-25 1999-07-13 Prostate specific fusion protein compositions
US09/439,313 US6329505B1 (en) 1997-02-25 1999-11-12 Compositions and methods for therapy and diagnosis of prostate cancer
US44368699A 1999-11-18 1999-11-18

Publications (1)

Publication Number Publication Date
CO5450246A1 true CO5450246A1 (en) 2004-10-29

Family

ID=40913635

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00052321A CO5450246A1 (en) 1999-07-13 2000-07-12 VACCINE

Country Status (2)

Country Link
JP (1) JP2009142284A (en)
CO (1) CO5450246A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210318317A1 (en) * 2018-10-04 2021-10-14 Konica Minolta, Inc. Method for acquiring auxiliary information

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ337446A (en) * 1997-02-25 2001-02-23 Corixa Corp Immunogenic portions of a prostate protein and their use in immunotherapy of prostate cancer and methods for their use
WO1998037418A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
WO1998050567A1 (en) * 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
JP2002518048A (en) * 1998-06-22 2002-06-25 インサイト・ファーマスーティカルズ・インコーポレイテッド Prostate cancer-related genes

Also Published As

Publication number Publication date
JP2009142284A (en) 2009-07-02

Similar Documents

Publication Publication Date Title
Lee et al. Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials
BR9812472A (en) Specific mamaglobin vaccine, process to treat a patient with a tumor that expresses mamaglobin, and isolated and purified polypeptide
AU3472299A (en) Rna cancer vaccine and methods for its use
ES2054040T3 (en) NEW GALLENIC FORM OF PHENOFIBRATE.
CY1106103T1 (en) METHOD FOR SEPARATION OF ROTAI VARIANTS AND LIVE ATTENUATED ROTAI VACCINE
PE20050712A1 (en) RG1 ANTIBODIES
TR200002731T2 (en) Methods for the identification, composition and use of inductors and inhibitors of proteolytic antibodies
WO2002022686A3 (en) Defensin-antigen fusion proteins
ATE315090T1 (en) VACCINE PRODUCTION OF THE BACILLUS ANTHRACIS PROTECTIVE ANTIGEN
ATE286745T1 (en) USE OF ANTIBODIES FOR VACCINATION AGAINST CANCER
CY1105179T1 (en) DRUGS FOR THE IMMUNE TREATMENT OF MALIGNANT TUMORS
JP2003530088A5 (en)
CO5450246A1 (en) VACCINE
WO2001035989A3 (en) Use of anti-idiotypical antibodies as vaccines against cancer
FR2746110B1 (en) METHOD OF TREATING GENE THERAPY OF HUMAN TUMORS AND CORRESPONDING RECOMBINANT VIRUSES
AR036793A1 (en) NUCLEIC ACID VACCINES USING NUCLEIC ACIDS THAT CODIFY A TUMOR ANTIGEN WITH A NUCLEIC ACID CODIFYING A CYTOKIN AS AN ADJUTIVE
PT1272652E (en) HERPES VIRUS FOR IMMUNITY MODULATION
UY26266A1 (en) ANTIGEN ASSOCIATED WITH TUMORS (R11) LAW 17164
ATE234628T1 (en) THERAPEUTIC APPLICATIONS OF ANTIGENS OR EPITOPES ASSOCIATED WITH INCOMPLETE CELLULAR PEPTIDE PROCESSING, E.G.: EXPRESSED IN RMA-S CELLS TRANSFECTED WITH B7-1 GENE
DE69922804D1 (en) USE OF POLYMERS OF HYALURONIC ACID FOR THE MUCOSAL RELEASE OF VACCINES AND ADJUVANTIES
UY27060A1 (en) VACCINE COMPOSITION CONTAINING TRANSFORMING GROWTH FACTOR (TGF-ALFA). ITS USE IN MALIGNAL DISEASE THERAPY
AR023794A1 (en) ANTIGEN ASSOCIATED WITH TUMORS
AR033378A1 (en) DERIVATIVE OF ANTIGEN OF PROSTASE, NUCLEIC ACID SEQUENCE THAT CODIFIES IT, VECTOR OF EXPRESSION CONTAINING THE PREVIOUS, CELLULATED BONE TRANSFORMED WITH SUCH SEQUENCE OF A NUCLEIC ACID OR SUCH VECTOR, VACCINE THAT UNDERSTANDS THE NUMBER OF DERIVATIVE OF NUT USE OF
UY26127A1 (en) ANTIGEN ASSOCIATED WITH TUMORS
EA199800750A1 (en) HIV SYNTHETIC GENES

Legal Events

Date Code Title Description
FA Application withdrawn